

Deutsche Forschungsgemeinschaft · 53170 Bonn, Germany

European Commission  
Directorate General for Health & Consumers  
Commissioner John Dalli

sanco-pharmaceuticals@ec.europa.eu

Prof. Dr.-Ing. Matthias Kleiner

**Deutsche  
Forschungsgemeinschaft**

German Research Foundation

Kennedyallee 40  
53175 Bonn, Germany

Please direct enquiries to:  
Dr. Frank Wissing  
Telefon: +49 228 885-2735  
Telefax: +49 228 885-2777  
frank.wissing@dfg.de  
www.dfg.de

11 May 2011

**Ref.: Response to Concept Paper Revision 'Clinical Trials Directive'  
2001/20/EC**


Dear Commissioner Dalli,

The Deutsche Forschungsgemeinschaft (German Research Foundation – DFG) welcomes the opportunity to comment on the Concept Paper 'Clinical Trials Directive' 2001/20/EC.

In keeping with its mandate to be the voice of science in Germany, the DFG has consulted the scientific community and deliberated the Concept Paper in its Senate Commission on Clinical Research. Taking these views into account, the DFG is pleased to bring its position to the attention of the Commission. Please find enclosed the response to the Concept Paper on the revision of the 'Clinical Trials Directive' 2001/20/EC.

I hope that these views and recommendations will lead to further improved provisions on the conduct of clinical trials and, thereby, advance patient-oriented clinical research to the benefit of patients in Europe and worldwide.

Yours sincerely,



Matthias Kleiner